Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Asthma

Novel once-daily fixed-dose ICS–LABA improves lung function over ICS monotherapy, research finds

A study in The Lancet Respiratory Medicine indicates that a once-daily fixed-dose combination of inhaled corticosteroids and long-acting β2-adrenoceptor agonist significantly improves lung function over inhaled corticosteroids alone.

Woman using an asthma inhaler

Source: Shutterstock.com

The researchers suggested that a once-daily fixed-dose of inhaled corticosteroids and long-acting β2-adrenoceptor agonist may be an effective treatment option for patients with inadequately controlled asthma, particularly those who find twice-daily teatment burdensome

A once-daily fixed-dose combination of inhaled corticosteroids (ICS) and long-acting β2-adrenoceptor agonist (LABA) significantly improved lung function over ICS alone, a phase III study has concluded (9 July 2020)[1].

The participants were randomly assigned to either high- or medium-dose mometasone furoate plus indacaterol acetate (MF–IND) taken once daily; high- or medium-dose MF taken twice and once daily, respectively; or high-dose fluticasone propionate–salmeterol xinafoate (FLU–SAL) taken twice daily.

The researchers found that high- and medium-dose MF–IND showed superiority in improving trough FEV1, compared with corresponding MF doses from baseline at week 26. Furthermore, high-dose MF–IND was non-inferior to twice-daily high-dose FLU–SAL in improving trough FEV1 from baseline at week 26. These changes were sustained for the full 52 weeks of the study.

The researchers explained that the fixed-dose combination of ICS and LABA is the preferred step-up treatment option for patients with asthma that is inadequately controlled on ICS monotherapy.

“Once-daily MF–IND might be an effective treatment option in patients with inadequately controlled asthma, particularly in those patients who find a twice-daily treatment option to be burdensome,” they concluded.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2020.20208280

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.